Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Avalo Therapeutics director Kevin Robert Lind received a grant of stock options as part of his compensation. On March 31, 2026, he was awarded options to purchase 1,370 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The filing notes these options were granted on March 31, 2026 and are 100% vested, meaning they are fully exercisable immediately. After this grant, Lind holds options covering 1,370 shares, which expire on March 31, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lind Kevin Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,370	$12.13	$17K

Holdings After Transaction: Stock Option (Right to Buy) — 1,370 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Options granted: 1,370 options Exercise price: $14.93 per share Underlying shares: 1,370 shares +3 more

6 metrics

Options granted 1,370 options Stock Option (Right to Buy) grant on March 31, 2026

Exercise price $14.93 per share Conversion or exercise price for the granted options

Underlying shares 1,370 shares Common stock underlying the stock options

Total options after grant 1,370 options Total derivative holdings following the reported transaction

Grant vesting 100% vested Options granted on March 31, 2026 are fully vested

Expiration date March 31, 2036 Expiration of the stock options if not exercised

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, vested

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vested financial

"The options were granted on March 31, 2026, and are 100% vested."

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last)

(First)

(Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.93	03/31/2026		A		1,370		⁽¹⁾	03/31/2036	Common Stock	1,370	$12.13	1,370	D

Explanation of Responses:

1. The options were granted on March 31, 2026, and are 100% vested.

	/s/ Christopher Sullivan, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Avalo Therapeutics (AVTX) disclose in this Form 4 filing?

Avalo Therapeutics disclosed that director Kevin Robert Lind received a grant of stock options. The award covers 1,370 shares of common stock, providing the right to buy those shares at a fixed exercise price of $14.93 per share, exercisable through March 31, 2036.

How many Avalo Therapeutics (AVTX) options were granted to Kevin Robert Lind?

Kevin Robert Lind was granted stock options for 1,370 shares of Avalo Therapeutics common stock. These options give him the right to purchase up to 1,370 shares at a predetermined exercise price, functioning as equity-based compensation for his role as a director of the company.

What is the exercise price of the new Avalo Therapeutics (AVTX) options?

The newly granted Avalo Therapeutics stock options have an exercise price of $14.93 per share. This means Lind can buy Avalo common shares at $14.93 regardless of future market prices, as long as he exercises the options before they expire in 2036.

When do Kevin Robert Lind’s Avalo Therapeutics (AVTX) options vest and expire?

The options granted to Kevin Robert Lind are 100% vested as of March 31, 2026, according to the filing footnote. They remain exercisable until March 31, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to buy shares.

How many Avalo Therapeutics (AVTX) options does Kevin Robert Lind hold after this grant?

Following this grant, Kevin Robert Lind holds stock options covering 1,370 shares of Avalo Therapeutics common stock. This total matches the new award, indicating this filing reflects his current option position related to this grant as of the reported date.

Is this Avalo Therapeutics (AVTX) Form 4 a market purchase or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market purchase. The transaction code is “A,” described as a grant, award, or other acquisition, and the footnote confirms the options were granted on March 31, 2026 and are fully vested.